Clinical Trials Logo

Alpha 1-Antitrypsin Deficiency clinical trials

View clinical trials related to Alpha 1-Antitrypsin Deficiency.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06389877 Not yet recruiting - Clinical trials for Alpha 1-Antitrypsin Deficiency

A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Start date: May 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, multicenter, open-label, dose-exploration (Phase 1) and dose-expansion (Phase 2) study to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease and to determine the optimal biological dose (OBD).

NCT ID: NCT06029543 Not yet recruiting - COPD Clinical Trials

Permian Health Women's Lung Health Study

WLHS
Start date: December 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this cross-sectional observational study is to estimate the prevalence of lung function impairment as measured by spirometry in a population of Gambian women aged 15 and older. The main question[s] it aims to answer are: - What is the prevalence of lung function impairment in Gambian women - What is the prevalence of eosinophilic inflammation in Gambian women Consenting participants will undergo - Spirometry - Fractional exhaled nitric oxide (FENO) testing - α1-antitrypsin testing in patients with lung function impairment as assessed by spirometry

NCT ID: NCT05897424 Not yet recruiting - Emphysema Clinical Trials

Open Label Extension Study of INBRX-101 in Adults With AATD Emphysema

ELEVAATE OLE
Start date: June 2024
Phase: Phase 2
Study type: Interventional

Phase 2 open label extension study to evaluate INBRX-101 in adults with AATD emphysema

NCT ID: NCT05622838 Not yet recruiting - Pre-Eclampsia Clinical Trials

Maternal alpha1 Antitrypsin as a Marker of Intrauterine Growth Restriction in Pre-eclamptic Women

Start date: December 2022
Phase:
Study type: Observational

Intrauterine growth restriction (IUGR) is defined as a velocity of fetal growth less than the normal fetus growth potential for a specific neonate as per the race and gender. These neonates face many acute problems during peripartum and after birth .The causes of IUGR may be maternal, placental, fetal or genetic and also due to combination of any of these factors. Knowledge of etiologies of fetal growth restriction (FGR) is essential, so that future care can be targeted at prevention . It is apparent that FGR is primarily caused by placental dysfunction (PIH&PE), insufficiency that lead to reduced fetal growth overall. FGR is associated with lifelong burden of chronic diseases including metabolic, respiratory, cardiovascular and neurological deficits. Pre-eclampsia (PE) is diagnosed by the combined presentation of high blood pressure and proteinuria. New definitions also include maternal organ dysfunction, such as renal, liver, neurological or haematological complications, uteroplacental dysfunction, or FGR . In an attempt to correct fetus reduced supply the placenta release various cytokines and markers as Alpha-1 anti-trypsin (AAT). The Golgi apparatus secretes this cytokine in placental cytotrophoblast and blood vessels. AAT is antinflammatory antiprotease protective molecule. AAT rises during normal pregnancy. The suboptimal rise of AAT in pregnancy are liable for increased obstetrical complications like abortion, preterm labor. AAT levels were found decreased in placenta tissues from women with PE compared that of healthy women. Although AAT deficiency is associated with several pregnancy and placental disorders, little is known regarding AAT levels and PE .